Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Hormonal antineoplastic drugs
Rezvilutamide
Другие языки:

    Rezvilutamide

    Подписчиков: 0, рейтинг: 0
    Rezvilutamide
    Rezvilutamide.png
    Clinical data
    Other names SHR3680
    Drug class Nonsteroidal antiandrogen
    Identifiers
    • 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
    CAS Number
    PubChem CID
    UNII
    Chemical and physical data
    Formula C22H20F3N3O4S
    Molar mass 479.47 g·mol−1
    3D model (JSmol)
    • CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC[C@H](CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
    • InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1
    • Key:KRBMOYIWQCZVHA-INIZCTEOSA-N

    Rezvilutamide (INN), sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer. It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide. The drug was developed by Jiangsu Hengrui Medicine. Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.



    Новое сообщение